Diffuse Optical Monitoring With Inhaled Nitric Oxide
Active, not recruiting · Phase 2 · NCT03023449
Conditions: Stroke
At a glance
- Research payments reported, 2025
- $15,525
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- Steven Messe (with Mallinckrodt)
- Tested
- Nitric Oxide (drug)
- Dates
- Started 2017-04-04; completion 2026-07
- Results posted
- Not yet
This study is a non-randomized, Phase 2 clinical trial designed to measure the cerebral blood flow (CBF) response to inhaled nitric oxide in acute ischemic stroke patients and healthy subjects. The monitoring is a 35 minute session during which cerebral hemodynamics will be monitored with both diffuse correlation spectroscopy (DCS) and transcranial doppler ultrasonography (TCD) while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide (NO)/nitrogen dioxide (NO2) concentration, are continuously monitored.
From ClinicalTrials.gov, last updated 2025-08-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mallinckrodt Hospital Products Inc. reported $15,525 in research payments for this study in 2025 (1 payments).
Products named: Inomax
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.